Leena Gandhi on the results of KEYNOTE-189
Interviewpartner:
Leena Gandhi, MD, PhD
Redaktion:
Dr. Gerhard Emrich
Produktion:
Oliver Eberhardt
Warning : Undefined property: medonline\theme\lib\templates\MoSingle::$ID in
/appl/www/htdocs/medonline/web/app/themes/mydailyapplenew/templates/entry-meta-video.php on line
56
veröffentlicht am Warning : Undefined property: medonline\theme\lib\templates\MoSingle::$postId in /appl/www/htdocs/medonline/web/app/themes/mydailyapplenew/templates/entry-meta-video.php on line 59
Leena Gandhi, MD, PhD, associate professor in the Department of Medicine and director of Thoracic Medical Oncology Program, Perlmutter Cancer Center at NYU Langone Health speaks about the results of KEYNOTE-189 that showed that the combination of immuntherapy and chemotherapy was significantly better in terms of ORR, PFS and OS compared with chemotherapy alone in patients with newly diagnosed metastatic NSCLC.
Reference:Gandhi L et al., abstract CT075: KEYNOTE-189: Randomized, double-blind, phase 3 study of pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum as first-line therapy for metastatic NSCLC